TEADCO Ph 1b/2 basket trial of ODM-212 + SoC initiated in patients with select advanced solid tumors April 28, 2026
Dose expansion in clinical study of spevatamig + chemo for treatment of biliary tract cancer April 28, 2026
ADCE-T02 enters cohort expansion portion of the Tiffany-01 study in advanced solid tumors April 28, 2026
First Pancreatic Cancer Patient in Europe treated with Alpha DaRT® in French Multicenter ACAPELLA Clinical Trial April 28, 2026
Ph 3 STAR-121 study of domvanalimab, zimberelimab and chemo vs pembrolizumab + chemo in 1L NSCLC to be discontinued April 28, 2026
First US Site Activated for Ongoing International Ph 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced NSCLC April 21, 2026
Nature Medicine Publishes Results Showing Doubling of the Rate of Survival with Elraglusib + Chemo in 1L Metastatic Pancreatic Ductal Adenocarcinoma April 21, 2026
Positive PDS01ADC Interim Ph 2 Trial Data from Stage 1 of NCI-led Metastatic CRC Trial Published April 21, 2026
Recruitment in AMPLICITY trial halted after three Dose Limiting Toxicities (DLTs) related to mFOLFIRINOX April 15, 2026
First Patient Dosed in Ph 3 RASolute 303 Trial of Daraxonrasib in 1L Metastatic Pancreatic Cancer April 7, 2026
Rinzimetostat RP3D in Combination with Darolutamide selected for Himalayas-1 Ph 3 Global Study with Dose Optimization Data April 7, 2026
First-Patient-In for Ph 1 Trial of IDE574 in Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer April 7, 2026
First-Patient-In for Ph 1 Combination Study of IDE849 and IDE161 in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NECs, and Melanoma April 7, 2026
QUILT-2.005 randomized clinical trial on track for final analysis and supplemental BLA submission in 2026 for the BCG-naïve NMIBC carcinoma in situ March 31, 2026
First Patient dosed in Ph 1 Trial of CLIO-8221 in Advanced HER2-Expressing Solid Tumors March 31, 2026
First Patient Dosed in Ph 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO) for Relapsed/Refractory Multiple Myeloma March 31, 2026
